Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.48% | -5.80% | -22.84% | -4.88% | -4.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.48% | -5.80% | -22.84% | -4.88% | -4.16% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -12.48% | -5.80% | -22.84% | -4.88% | -4.16% |
| SG&A Expenses | -20.00% | -22.23% | -0.81% | 6.31% | 3.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.81% | -23.42% | -11.01% | -24.19% | -12.97% |
| Operating Income | 25.14% | 32.51% | 3.79% | 34.12% | 16.95% |
| Income Before Tax | 24.02% | 33.27% | 1.12% | 33.84% | 16.20% |
| Income Tax Expenses | -259.50% | 33.12% | 74.26% | -109.36% | -925.00% |
| Earnings from Continuing Operations | 27.32% | 33.28% | -2.55% | 42.00% | 17.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.32% | 33.28% | -2.55% | 42.00% | 17.26% |
| EBIT | 25.14% | 32.51% | 3.79% | 34.12% | 16.95% |
| EBITDA | 27.44% | 33.85% | 3.25% | 34.58% | 17.39% |
| EPS Basic | 27.96% | 33.75% | -1.90% | 42.34% | 17.78% |
| Normalized Basic EPS | 24.69% | 35.07% | 6.92% | 34.23% | 16.72% |
| EPS Diluted | 27.96% | 33.75% | -1.90% | 42.34% | 17.78% |
| Normalized Diluted EPS | 24.69% | 35.07% | 6.92% | 34.23% | 16.72% |
| Average Basic Shares Outstanding | 0.89% | 0.71% | 0.63% | 0.60% | 0.63% |
| Average Diluted Shares Outstanding | 0.89% | 0.71% | 0.63% | 0.60% | 0.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |